<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Transverse myelitis: Treatment and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Transverse myelitis: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Transverse myelitis: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin Greenberg, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2764559587"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute transverse myelitis (TM) is a rare, acquired neuroimmune spinal cord disorder that can present with the rapid onset of weakness, sensory alterations, and bowel or bladder dysfunction. TM can occur as an independent entity, usually as a postinfectious complication, but TM also exists on a continuum of neuroinflammatory disorders that includes acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), and acute flaccid myelitis (AFM). The clinical features, diagnostic workup, and acute and chronic therapies differ among these forms of TM.</p><p>This topic will review the treatment and prognosis of acute TM. Other aspects of TM are discussed separately. (See  <a class="medical medical_review" href="/d/html/14088.html" rel="external">"Transverse myelitis: Etiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H743992726"><span class="h1">IDIOPATHIC TRANSVERSE MYELITIS</span><span class="headingEndMark"> — </span>TM is considered idiopathic when the cause is not identified despite a comprehensive evaluation. (See  <a class="medical medical_review" href="/d/html/14088.html" rel="external">"Transverse myelitis: Etiology, clinical features, and diagnosis", section on 'Idiopathic'</a>.)</p><p class="headingAnchor" id="H2372561879"><span class="h2">Initial therapy of idiopathic TM</span><span class="headingEndMark"> — </span>Acute attacks of idiopathic TM are typically treated with a short course of high-dose intravenous glucocorticoids, with or without plasma exchange (PLEX).</p><p class="headingAnchor" id="H2023277405"><span class="h3">TM without motor impairment</span><span class="headingEndMark"> — </span>We suggest high-dose intravenous glucocorticoid treatment for patients with acute idiopathic TM. Glucocorticoid treatment should be started as soon as possible; there are few contraindications. Thus, a clinician does not need to wait for the workup to be complete before starting therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid regimens</strong> – Our preferred regimens are <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> (30 mg/kg up to 1000 mg daily) or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (120 to 200 mg daily for adults) for three to five days. A longer glucocorticoid treatment course or more aggressive regimens may be warranted based upon the clinical course and radiologic parameters; examples include patients with severe sensory deficits that affect activities of daily living, lesions near the brainstem, or poor response to initial therapy with minimal improvement of lesion enhancement on magnetic resonance imaging (MRI).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Short-term high-dose glucocorticoid therapy is associated with relatively few side effects in most patients, although mental status changes, increased susceptibility to infection, and gastric disturbance are potential complications. Psychiatric adverse effects can include increased depressive, manic, and hypomanic symptoms [<a href="#rid1">1,2</a>]. To mitigate these adverse effects, strategies include the prophylactic use of a proton pump inhibitor in the morning and/or low-dose <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a> as needed at night while on glucocorticoid treatment. Patients with diabetes mellitus may need to be hospitalized to monitor glucose levels.</p><p></p><p>Intravenous glucocorticoids have long been considered the standard of care and first-line therapy in acute idiopathic TM. Even without placebo-controlled trials evaluating glucocorticoids specifically in TM [<a href="#rid3">3</a>], there is evidence that intravenous glucocorticoids are effective in the short term in acute inflammatory central nervous system (CNS) diseases like TM, such as multiple sclerosis. (See  <a class="medical medical_review" href="/d/html/1698.html" rel="external">"Treatment of acute exacerbations of multiple sclerosis in adults", section on 'Initial therapy with glucocorticoids'</a>.)</p><p class="headingAnchor" id="H144863371"><span class="h3">TM with motor impairment</span><span class="headingEndMark"> — </span>In addition to high-dose glucocorticoid therapy (see <a class="local">'TM without motor impairment'</a> above), we suggest treatment with PLEX for patients who have acute TM with motor impairment [<a href="#rid4">4</a>]. While there is a lack of prospective studies determining the best timing and sequencing of PLEX relative to glucocorticoids, there are studies that have supported a unique response to PLEX for patients with anti-aquaporin 4 (AQP4)-mediated myelitis [<a href="#rid5">5,6</a>]. Better outcomes have been observed in patients with earlier PLEX. Given that patients with a first event of TM require intervention before all test results are back, it is our practice to start PLEX early after admission for patients with significant deficits; waiting until glucocorticoid treatments are completed is not necessary.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PLEX regimens</strong> – Our preferred regimen is five to seven treatments, each with exchanges of 1.1 to 1.5 plasma volumes, every other day for 8 to 14 days; alternatively, the first two PLEX treatments can be given on successive days, with the remaining three treatments given every other day [<a href="#rid7">7</a>]. Most patients can receive albumin instead of plasma as the replacement fluid, but fibrinogen levels should be monitored.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects of PLEX</strong> – Complications of PLEX are presented separately. (See  <a class="medical medical_review" href="/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a> and  <a class="medical medical_review" href="/d/html/7942.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Complications"</a>.)</p><p></p><p>Retrospective observational studies suggest that PLEX may be effective for some patients with acute CNS demyelinating diseases, including patients with severe idiopathic TM, who fail to respond to high-dose glucocorticoid treatment [<a href="#rid8">8-12</a>].</p><p class="headingAnchor" id="H3789749584"><span class="h2">Subsequent therapy for patients who progress</span><span class="headingEndMark"> — </span>For patients who continue to progress despite intravenous glucocorticoid and PLEX treatment, we confirm the diagnosis of idiopathic TM with special attention to ruling out vascular myelopathies. We then consider the use of intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (800 to 1200 mg/m<sup>2</sup> administered as a single pulse dose) [<a href="#rid13">13</a>], using shared decision-making discussions with the patient that emphasize uncertain benefits and potential harms of treatment, including hemorrhagic cystitis and cytopenia.</p><p class="headingAnchor" id="H2021500041"><span class="h2">Recurrent idiopathic TM</span><span class="headingEndMark"> — </span>For patients with recurrent idiopathic TM, chronic immunomodulatory therapy is a reasonable treatment option. Each acute event is treated with steroids with or without PLEX as noted above (see <a class="local">'Initial therapy of idiopathic TM'</a> above), and we repeat the work-up to look for an underlying cause. When a systemic cause cannot be found, we offer patients treatment with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> (2 to 3 g daily) or intravenous <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (1000 mg every six months) in a shared decision-making process, but other immunosuppressive regimens may be used in patients with systemic inflammatory disease [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H492144131"><span class="h2">Symptomatic care</span></p><p class="headingAnchor" id="H2877191419"><span class="h3">Rehabilitation</span><span class="headingEndMark"> — </span>Rehabilitation after TM is poorly studied, but the problems are similar to those encountered with recovery from spinal cord injury in general, where more published evidence is available [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease"</a>.)</p><p>Most patients with acute TM will need acute rehabilitation, while approximately two-thirds will need long-term rehabilitation [<a href="#rid15">15</a>].</p><p>Physical and occupational therapy for acute TM should be started early (as soon as the patient is medically stable) to begin strengthening, range-of-motion, and compensatory strategies along with assessment and fitting for assistive devices [<a href="#rid13">13</a>]. These measures help to improve function and avoid problems like skin breakdown and joint contractures.</p><p class="headingAnchor" id="H4035445222"><span class="h3">Complications of TM</span><span class="headingEndMark"> — </span>Sequelae of TM may include a number of complications and residual effects including bladder and bowel dysfunction, sexual dysfunction, skin breakdown, spasticity, pain, immobility, loss of self-care (eg, bathing, dressing, eating), and psychosocial problems including depression and suicidality [<a href="#rid13">13</a>].</p><p>Management of specific complications is reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Bowel dysfunction (see  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Gastrointestinal complications'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bladder dysfunction (see  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Bladder dysfunction'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sexual dysfunction (see  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Sexual dysfunction'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin breakdown (see  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Pressure ulcers'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spasticity (see  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Spasticity'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain (see  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Pain syndromes'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immobility (see  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Musculoskeletal complications'</a> and  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Functional deficits'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychosocial problems (see  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Psychiatric complications'</a>)</p><p></p><p class="headingAnchor" id="H3065203833"><span class="h2">Prognosis</span></p><p class="headingAnchor" id="H2144928306"><span class="h3">Recovery</span><span class="headingEndMark"> — </span>Most patients with idiopathic TM have at least a partial recovery, which usually begins within one to three months and continues with exercise and rehabilitation therapy [<a href="#rid16">16</a>]. Recovery can proceed over years. Older studies reported that some degree of disability persisted in approximately 40 percent of patients [<a href="#rid16">16,17</a>]. These outcomes, however, were recorded before neuromyelitis optica spectrum disorder (NMOSD) was clearly defined as a disease and during a period when patients were not routinely treated with PLEX acutely. We suspect that the outcomes have improved over time.</p><p>A very rapid onset with paraplegia and spinal shock has been associated with poorer outcomes [<a href="#rid16">16,18-20</a>]. Age younger than three years at onset of TM has also been associated with a poorer outcome in one case series [<a href="#rid17">17</a>].</p><p>Research is needed to define biomarkers of disease that predict outcome and risk of recurrence. Ongoing aggressive rehabilitation with activity-based therapy is recommended in these patients. (See <a class="local">'Rehabilitation'</a> above.)</p><p class="headingAnchor" id="H2356765556"><span class="h3">Recurrence</span><span class="headingEndMark"> — </span>The<strong> </strong>majority of patients with idiopathic TM experience a monophasic disease. Recurrence has been reported in 25 to 33 percent of patients with idiopathic TM [<a href="#rid21">21-23</a>], but these studies include cohorts that predated the widespread use of testing for myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> G (IgG) autoantibodies. In addition, TM can recur in a subset of patients with a history of systemic autoimmune disease. With disease-associated TM, the recurrence rate may be as high as 70 percent [<a href="#rid24">24-26</a>].</p><p>Features present at the time of the initial acute onset of TM that may predict recurrence  (<a class="graphic graphic_table graphicRef88919" href="/d/graphic/88919.html" rel="external">table 1</a>) include the following [<a href="#rid23">23,27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Multifocal or longitudinally extensive lesions in the spinal cord on MRI</p><p class="bulletIndent1"><span class="glyph">●</span>Brain lesions on MRI</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of one or more autoantibodies (antinuclear antibody [ANA], double-stranded deoxyribonucleic acid [dsDNA], phospholipid, cytoplasmic antineutrophil cytoplasmic antibodies [c-ANCA])</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying mixed connective tissue disease</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of oligoclonal bands in the cerebrospinal fluid</p><p class="bulletIndent1"><span class="glyph">●</span>Seropositivity for AQP4 IgG autoantibody (see  <a class="medical medical_review" href="/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis", section on 'AQP4 autoantibody'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent seropositivity for the MOG IgG autoantibody (see  <a class="medical medical_review" href="/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'MOG autoantibody'</a>)</p><p></p><p>In patients with acute complete idiopathic TM (ie, with complete or near complete neurologic deficits including paresis, sensory loss, and autonomic dysfunction below the level of the lesion), MRI of the brain is almost always normal. These patients are less likely to present with oligoclonal bands, less likely to relapse with a second bout of myelitis, and less likely to transition to clinically definite multiple sclerosis. (See <a class="local">'Progression to multiple sclerosis'</a> below.)</p><p class="headingAnchor" id="H397791450"><span class="h3">Progression to multiple sclerosis</span><span class="headingEndMark"> — </span>The risk of progression to multiple sclerosis for patients presenting with acute TM is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis", section on 'Risk of progression to multiple sclerosis'</a>.)</p><p class="headingAnchor" id="H708076344"><span class="h1">SECONDARY (DISEASE-RELATED) TRANSVERSE MYELITIS</span></p><p class="headingAnchor" id="H2809736779"><span class="h2">CNS demyelinating disorders</span><span class="headingEndMark"> — </span>TM is a common manifestation of multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and acute disseminated encephalomyelitis (ADEM).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute treatment</strong> – Acute attacks of TM in patients with most types of central nervous system (CNS) demyelinating disorders are typically treated with a short course of high-dose intravenous glucocorticoids and, in cases of NMOSD or patients with significant motor deficits, with adjunctive plasma exchange (PLEX). The treatment of these conditions is reviewed in detail elsewhere:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple sclerosis (see  <a class="medical medical_review" href="/d/html/1698.html" rel="external">"Treatment of acute exacerbations of multiple sclerosis in adults", section on 'Initial therapy with glucocorticoids'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NMOSD (see  <a class="medical medical_review" href="/d/html/134223.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis", section on 'Acute treatment'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MOGAD (see  <a class="medical medical_review" href="/d/html/132021.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis", section on 'Treatment of acute attacks'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ADEM (see  <a class="medical medical_review" href="/d/html/14087.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in adults", section on 'Initial therapy'</a> and  <a class="medical medical_review" href="/d/html/6208.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in children: Treatment and prognosis", section on 'Initial immunotherapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Attack prevention – </strong>Prevention of recurrent attacks for secondary (disease-related) TM due to CNS demyelinating disorders primarily involves immune-modulating disease-modifying therapy, as reviewed separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple sclerosis (see  <a class="medical medical_review" href="/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"</a> and  <a class="medical medical_review" href="/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/d/html/6223.html" rel="external">"Treatment and prognosis of pediatric multiple sclerosis"</a> and  <a class="medical medical_review" href="/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/d/html/128298.html" rel="external">"Treatment of primary progressive multiple sclerosis in adults"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NMOSD (see  <a class="medical medical_review" href="/d/html/134223.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis", section on 'Attack prevention'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MOGAD (see  <a class="medical medical_review" href="/d/html/132021.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis", section on 'Approach to attack prevention'</a>)</p><p></p><p class="headingAnchor" id="H1267648814"><span class="h2">Systemic autoimmune disorders</span><span class="headingEndMark"> — </span>Acute attacks of TM in patients with most types of systemic autoimmune disorders are typically treated with a short course of high-dose intravenous glucocorticoids, with or without PLEX, similar to acute idiopathic TM (see <a class="local">'Initial therapy of idiopathic TM'</a> above). However, in severe cases of myelitis secondary to systemic lupus erythematosus, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> may be beneficial. In the clinical experience of the authors, intravenous cyclophosphamide for patients with aggressive TM has been associated with good outcomes, but this was most notable in patients with systemic lupus erythematosus. One small, uncontrolled observational study provides additional limited support for the use of cyclophosphamide in this subset of patients [<a href="#rid11">11</a>]. Given the methodologic limitations of this study, this finding requires confirmation in randomized controlled trials.</p><p>The approach to the treatment of acute TM, attack prevention, and maintenance therapy for several systemic inflammatory disorders is discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Behçet syndrome (see  <a class="medical medical_review" href="/d/html/8239.html" rel="external">"Treatment of Behçet syndrome", section on 'Neurologic disease'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis (see  <a class="medical medical_review" href="/d/html/4834.html" rel="external">"Neurologic sarcoidosis", section on 'Treatment'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sjögren’s disease (see  <a class="medical medical_review" href="/d/html/120953.html" rel="external">"Neurologic manifestations of Sjögren's disease", section on 'Focal or multifocal demyelination/inflammation'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus (see  <a class="medical medical_review" href="/d/html/4863.html" rel="external">"Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus", section on 'Myelitis'</a>)</p><p></p><p class="headingAnchor" id="H2893224456"><span class="h2">Paraneoplastic disorders</span><span class="headingEndMark"> — </span>Treatment for TM due to a paraneoplastic etiology includes glucocorticoids and PLEX as described above for acute idiopathic TM (see <a class="local">'Initial therapy of idiopathic TM'</a> above), but long-term remission is based on therapy directed at the underlying malignancy, along with immunotherapy in most cases [<a href="#rid28">28,29</a>]. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Treatment and prognosis'</a>.)</p><p class="headingAnchor" id="H1812979430"><span class="h2">Infectious causes</span><span class="headingEndMark"> — </span>Treatment of acute attacks of TM in rare patients with an infectious cause varies according to the specific infectious agent  (<a class="graphic graphic_table graphicRef121798" href="/d/graphic/121798.html" rel="external">table 2</a>). Glucocorticoids and antiviral agents are often used for acute TM associated with viral infections, but there is no high-quality evidence or consensus about management, and the use of anti-inflammatory therapies is controversial.</p><p>Refer to individual UpToDate topic reviews for specific antiviral and antimicrobial treatment recommendations.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2693.html" rel="external">"Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention", section on 'Treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/126102.html" rel="external">"Acute flaccid myelitis", section on 'Treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1282.html" rel="external">"Treatment and prevention of West Nile virus infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8293.html" rel="external">"Treatment of herpes zoster", section on 'Neurologic complications'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128001.html" rel="external">"Central nervous system tuberculosis: Treatment and prognosis", section on 'Transverse myelitis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8317.html" rel="external">"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H1855223969"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117065.html" rel="external">"Society guideline links: Multiple sclerosis and related disorders"</a>.)</p><p class="headingAnchor" id="H2599822950"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute treatment for idiopathic transverse myelitis (TM)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TM without motor impairment</strong> – For patients with acute idiopathic TM, we suggest high-dose intravenous glucocorticoid treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Our preferred regimens are <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> (30 mg/kg up to 1000 mg daily) or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (up to 200 mg daily for adults) for three to five days. (See <a class="local">'TM without motor impairment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TM with motor impairment </strong>– For patients with acute TM complicated by motor impairment, we suggest plasma exchange (PLEX) in addition to glucocorticoid treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Our preferred regimen is five treatments, each with exchanges of 1.1 to 1.5 plasma volumes, every other day for 10 days; alternatively, the first two PLEX treatments can be given on successive days, with the remaining three treatments given every other day. (See <a class="local">'TM with motor impairment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progression despite initial therapy</strong> – For patients with TM who continue to progress despite intravenous glucocorticoid and PLEX treatment, we confirm the diagnosis of idiopathic TM with special attention to ruling out vascular myelopathies. We then consider the use of intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>,<em> </em>using shared decision-making discussions with the patient. (See <a class="local">'Subsequent therapy for patients who progress'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Attack prevention</strong> – For patients with recurrent idiopathic TM, chronic immunomodulatory therapy is a reasonable treatment option, but supportive evidence is sparse. Using a shared decision-making process, we offer patients treatment with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> (2 to 3 g daily) or intravenous <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (1000 mg every six months), but other immunosuppressive regimens may be used in patients with systemic inflammatory disease [<a href="#rid14">14</a>]. (See <a class="local">'Recurrent idiopathic TM'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications of TM</strong> – Sequelae of TM may include several complications and residual effects including bladder and bowel dysfunction, sexual dysfunction, skin breakdown, spasticity, pain, immobility, loss of self-care (eg, bathing, dressing, eating), and psychosocial problems including depression and suicidality. Physical and occupational therapy for acute TM should be started early (as soon as the patient is medically stable). The management of specific complications is reviewed separately, with links to appropriate UpToDate topics listed above. (See <a class="local">'Rehabilitation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis of idiopathic TM</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Degree of recovery</strong> – Most patients with idiopathic TM have at least a partial recovery, which usually begins within one to three months and continues with exercise and rehabilitation therapy. Some degree of persistent disability is common. A very rapid onset with complete paraplegia and spinal shock has been associated with poorer outcomes. Recovery can continue over years. (See <a class="local">'Recovery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk of recurrence</strong> – Most patients with TM experience monophasic disease. Recurrence has been reported in 25 to 33 percent of patients with idiopathic TM, although this usually signals a systemic condition. With disease-associated (secondary) TM, the recurrence rate may be as high as 70 percent. (See <a class="local">'Recurrence'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk of multiple sclerosis</strong> – The risk of progression to multiple sclerosis for patients presenting with acute TM is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis", section on 'Risk of progression to multiple sclerosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary (disease-related) TM</strong> – The treatment of TM due to central nervous system (CNS) demyelinating disorders, systemic autoimmune disorders, paraneoplastic disorders, and infectious causes is reviewed separately, with links to appropriate UpToDate topics listed above. (See <a class="local">'Secondary (disease-related) transverse myelitis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Morrow SA, Barr J, Rosehart H, Ulch S. Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses. J Affect Disord 2015; 187:142.</a></li><li><a class="nounderline abstract_t">Lotan I, Fireman L, Benninger F, et al. Psychiatric side effects of acute high-dose corticosteroid therapy in neurological conditions. Int Clin Psychopharmacol 2016; 31:224.</a></li><li><a class="nounderline abstract_t">Scott TF, Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 77:2128.</a></li><li><a class="nounderline abstract_t">Greenberg BM. Treatment of acute transverse myelitis and its early complications. Continuum (Minneap Minn) 2011; 17:733.</a></li><li><a class="nounderline abstract_t">Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018; 89:346.</a></li><li><a class="nounderline abstract_t">Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler 2016; 22:185.</a></li><li><a class="nounderline abstract_t">Gwathmey K, Balogun RA, Burns T. Neurologic indications for therapeutic plasma exchange: an update. J Clin Apher 2011; 26:261.</a></li><li><a class="nounderline abstract_t">Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878.</a></li><li><a class="nounderline abstract_t">Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76:294.</a></li><li><a class="nounderline abstract_t">Bigi S, Banwell B, Yeh EA. Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination. J Child Neurol 2015; 30:874.</a></li><li><a class="nounderline abstract_t">Greenberg BM, Thomas KP, Krishnan C, et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007; 68:1614.</a></li><li><a class="nounderline abstract_t">Noland DK, Greenberg BM. Safety and efficacy of plasma exchange in pediatric transverse myelitis. Neurol Clin Pract 2018; 8:327.</a></li><li class="breakAll">Transverse myelitis. National Organization for Rare Disorders (NORD). https://rarediseases.org/rare-diseases/transverse-myelitis/ (Accessed on August 18, 2023).</li><li><a class="nounderline abstract_t">Kaplin AI, Krishnan C, Deshpande DM, et al. Diagnosis and management of acute myelopathies. Neurologist 2005; 11:2.</a></li><li><a class="nounderline abstract_t">Sadowsky CL, Becker D, Bosques G, et al. Rehabilitation in transverse myelitis. Continuum (Minneap Minn) 2011; 17:816.</a></li><li><a class="nounderline abstract_t">Defresne P, Hollenberg H, Husson B, et al. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol 2003; 18:401.</a></li><li><a class="nounderline abstract_t">Pidcock FS, Krishnan C, Crawford TO, et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007; 68:1474.</a></li><li><a class="nounderline abstract_t">de Seze J, Lanctin C, Lebrun C, et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005; 65:1950.</a></li><li><a class="nounderline abstract_t">Bruna J, Martínez-Yélamos S, Martínez-Yélamos A, et al. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler 2006; 12:169.</a></li><li><a class="nounderline abstract_t">Ganelin-Cohen E, Konen O, Nevo Y, et al. Prognostic Parameters of Acute Transverse Myelitis in Children. J Child Neurol 2020; 35:999.</a></li><li><a class="nounderline abstract_t">Seifert T, Enzinger C, Ropele S, et al. Relapsing acute transverse myelitis: a specific entity. Eur J Neurol 2005; 12:681.</a></li><li><a class="nounderline abstract_t">Kim KK. Idiopathic recurrent transverse myelitis. Arch Neurol 2003; 60:1290.</a></li><li><a class="nounderline abstract_t">Borchers AT, Gershwin ME. Transverse myelitis. Autoimmun Rev 2012; 11:231.</a></li><li><a class="nounderline abstract_t">Jeffery DR, Mandler RN, Davis LE. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol 1993; 50:532.</a></li><li><a class="nounderline abstract_t">Berman M, Feldman S, Alter M, et al. Acute transverse myelitis: incidence and etiologic considerations. Neurology 1981; 31:966.</a></li><li><a class="nounderline abstract_t">de Seze J, Stojkovic T, Breteau G, et al. Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. Brain 2001; 124:1509.</a></li><li><a class="nounderline abstract_t">Krishnan C, Kaplin AI, Pardo CA, et al. Demyelinating disorders: update on transverse myelitis. Curr Neurol Neurosci Rep 2006; 6:236.</a></li><li><a class="nounderline abstract_t">Flanagan EP, Keegan BM. Paraneoplastic myelopathy. Neurol Clin 2013; 31:307.</a></li><li><a class="nounderline abstract_t">Shah S, Vazquez Do Campo R, Kumar N, et al. Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments. Neurology 2021; 96:e632.</a></li></ol></div><div id="topicVersionRevision">Topic 142457 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26334182" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26938038" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Psychiatric side effects of acute high-dose corticosteroid therapy in neurological conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156988" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22810928" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of acute transverse myelitis and its early complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29030418" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25921047" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21915895" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neurologic indications for therapeutic plasma exchange: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589540" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21242498" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25246301" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485649" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30140584" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Safety and efficacy of plasma exchange in pediatric transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30140584" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Safety and efficacy of plasma exchange in pediatric transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15631640" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnosis and management of acute myelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22810933" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rehabilitation in transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12886975" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acute transverse myelitis in children: clinical course and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470749" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acute transverse myelitis in childhood: center-based analysis of 47 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380618" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Idiopathic acute transverse myelitis: application of the recent diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16629419" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32808576" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prognostic Parameters of Acute Transverse Myelitis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16128868" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Relapsing acute transverse myelitis: a specific entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12975297" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Idiopathic recurrent transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21621005" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8489410" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7196523" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Acute transverse myelitis: incidence and etiologic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11459743" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16635433" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Demyelinating disorders: update on transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23186906" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Paraneoplastic myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33208548" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
